Trial Profile

A Long-term, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of a Modigraf Based Immunosuppression Regimen in Paediatric Solid Allograft Recipients

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tacrolimus (Primary)
Indications Allotransplant rejection; Heart transplant rejection; Liver transplant rejection; Renal transplant rejection
Focus Adverse reactions; Therapeutic Use
Acronyms PROGRESSION
Sponsors Astellas Pharma; Astellas Pharma Europe Ltd

Most Recent Events

26 Mar 2022 This trial is completed in Belgium (End Date: 02 Apr 2017), according to European Clinical Trials Database.
02 Jul 2019 This trial is discontinued in UK (End Date: 31 Oct 2017), according to European Clinical Trials Database.
12 Dec 2017 This trial was discontinued in France, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com